Otamixaban
From Wikipedia, the free encyclopedia
Otamixaban
|
|
Systematic (IUPAC) name | |
methyl (2R,3R)-2-(3-carbamimidoylbenzyl)-3- {[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C25H26N4O4 |
Mol. mass | 446.498 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Otamixaban (INN) is an inhibitor of Factor Xa,[1] currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
[edit] See also
[edit] References
- ^ Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. PMID 17979700.
|